Aethlon Medical to Present at Virtual Investor Conferences in September
Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious diseases, has announced its participation in two virtual investor conferences in September 2024. The events are:
1. Life Sciences Investor Forum (Sept 19-20): James Frakes (Interim CEO/CFO) and Dr. Steven LaRosa (CMO) will present on Sept 19 at 1:30 pm ET. One-on-one meetings available.
2. Virtual Emerging Growth Conference (Sept 25): Presentation at 12:35 pm ET, followed by Q&A.
Both events offer live interaction, pre-registration, and archived webcasts. These conferences provide opportunities for investors to learn about Aethlon Medical's developments and engage with management directly.
Aethlon Medical (Nasdaq: AEMD), un'azienda che sviluppa prodotti per il cancro e le malattie infettive, ha annunciato la sua partecipazione a due conferenze virtuali per investitori a settembre 2024. Gli eventi sono:
1. Life Sciences Investor Forum (19-20 settembre): James Frakes (CEO/CFO ad interim) e il Dr. Steven LaRosa (CMO) presenteranno il 19 settembre alle 13:30 ET. Sono disponibili incontri one-to-one.
2. Virtual Emerging Growth Conference (25 settembre): Presentazione alle 12:35 ET, seguita da una sessione di domande e risposte.
Entrambi gli eventi offrono interazione dal vivo, preregistrazione e webcast archiviati. Queste conferenze offrono opportunità agli investitori per conoscere gli sviluppi di Aethlon Medical e interagire direttamente con la direzione.
Aethlon Medical (Nasdaq: AEMD), una empresa que desarrolla productos para el cáncer y enfermedades infecciosas, ha anunciado su participación en dos conferencias virtuales para inversores en septiembre de 2024. Los eventos son:
1. Life Sciences Investor Forum (19-20 de septiembre): James Frakes (CEO/CFO interino) y el Dr. Steven LaRosa (CMO) presentarán el 19 de septiembre a la 1:30 pm ET. Se disponen reuniones uno a uno.
2. Virtual Emerging Growth Conference (25 de septiembre): Presentación a las 12:35 pm ET, seguida de una sesión de preguntas y respuestas.
Ambos eventos ofrecen interacción en vivo, preinscripción y webcasts archivados. Estas conferencias ofrecen oportunidades para que los inversores conozcan los desarrollos de Aethlon Medical y se relacionen directamente con la dirección.
Aethlon Medical (Nasdaq: AEMD), 암 및 감염병을 위한 제품을 개발하는 회사가 2024년 9월 두 개의 가상 투자자 회의에 참여한다고 발표했습니다. 이 행사는 다음과 같습니다:
1. Life Sciences Investor Forum (9월 19-20일): 제임스 프레이크스(임시 CEO/CFO)와 스티븐 라로사 박사(CMO)가 9월 19일 오후 1:30 ET에 발표합니다. 일대일 미팅이 가능합니다.
2. Virtual Emerging Growth Conference (9월 25일): 오후 12:35 ET에 발표 후 Q&A가 진행됩니다.
두 행사 모두 실시간 상호작용, 사전 등록 및 아카이브된 웹캐스트를 제공합니다. 이러한 회의는 투자자들이 Aethlon Medical의 개발에 대해 배우고 경영진과 직접 소통할 수 있는 기회를 제공합니다.
Aethlon Medical (Nasdaq: AEMD), une entreprise développant des produits pour le cancer et les maladies infectieuses, a annoncé sa participation à deux conférences virtuelles pour investisseurs en septembre 2024. Les événements sont :
1. Life Sciences Investor Forum (19-20 septembre) : James Frakes (PDG/CFO par intérim) et Dr. Steven LaRosa (CMO) présenteront le 19 septembre à 13h30 ET. Des réunions individuelles sont disponibles.
2. Virtual Emerging Growth Conference (25 septembre) : Présentation à 12h35 ET, suivie d'une session de questions-réponses.
Les deux événements offrent une interaction en direct, une préinscription et des webcasts archivés. Ces conférences offrent aux investisseurs l'occasion d'en apprendre davantage sur les développements d'Aethlon Medical et d'interagir directement avec la direction.
Aethlon Medical (Nasdaq: AEMD), ein Unternehmen, das Produkte für Krebs und Infektionskrankheiten entwickelt, hat seine Teilnahme an zwei virtuellen Investorenkonferenzen im September 2024 angekündigt. Die Veranstaltungen sind:
1. Life Sciences Investor Forum (19.-20. September): James Frakes (Interim CEO/CFO) und Dr. Steven LaRosa (CMO) werden am 19. September um 13:30 Uhr ET präsentieren. Einzelgespräche sind verfügbar.
2. Virtual Emerging Growth Conference (25. September): Präsentation um 12:35 Uhr ET, gefolgt von einer Fragerunde.
Beide Veranstaltungen bieten Live-Interaktion, eine Voranmeldung und archivierte Webcasts. Diese Konferenzen bieten Investoren die Möglichkeit, mehr über die Entwicklungen von Aethlon Medical zu erfahren und direkt mit dem Management in Kontakt zu treten.
- None.
- None.
- September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief Financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this conference, hosted by virtualinvestorconferences.com, on Thursday, September 19, 2024 at 1:30 pm ET. Management will also be available for one-on-one meetings on September 19 and 20, 2024.
Interested investors can pre-register for the conference using this link, which will be a live interactive online event where investors can ask the company questions in real-time. An archived webcast will also be available after the event.
- September 25: Virtual Emerging Growth Conference: Mr. Frakes and Dr. LaRosa will present a company overview at this conference on Wednesday, September 25, 2024 at 12:35 pm ET.
After the presentation, management will open the floor for questions. Investors may submit questions in advance to questions@emerginggrowth.com or ask questions during the event.
Please register using this link to attend the virtual conference and receive any updates that are released.
An archived webcast will also be made available on www.emerginggrowth.com and on the Emerging Growth YouTube Channel, www.YouTube.com/emerginggrowthconference, which will be released after the event.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-virtual-investor-conferences-in-september-302250041.html
SOURCE Aethlon Medical, Inc.
FAQ
When is Aethlon Medical (AEMD) presenting at the Life Sciences Investor Forum in September 2024?
Who will be representing Aethlon Medical (AEMD) at the September 2024 investor conferences?
What is the date and time of Aethlon Medical's (AEMD) presentation at the Virtual Emerging Growth Conference?
Are one-on-one meetings available with Aethlon Medical (AEMD) management during the September 2024 conferences?